KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) EPS (Basic) (2016 - 2025)

Nektar Therapeutics has reported EPS (Basic) over the past 16 years, most recently at -$1.59 for Q4 2025.

  • Quarterly results put EPS (Basic) at -$1.59 for Q4 2025, down 369.49% from a year ago — trailing twelve months through Dec 2025 was -$6.65 (down 10.47% YoY), and the annual figure for FY2025 was -$9.73, down 12.1%.
  • EPS (Basic) for Q4 2025 was -$1.59 at Nektar Therapeutics, up from -$1.87 in the prior quarter.
  • Over the last five years, EPS (Basic) for NKTR hit a ceiling of $0.59 in Q4 2024 and a floor of -$790.0 in Q4 2021.
  • Median EPS (Basic) over the past 5 years was -$0.68 (2021), compared with a mean of -$40.41.
  • Biggest five-year swings in EPS (Basic): plummeted 121438.46% in 2021 and later soared 368.18% in 2024.
  • Nektar Therapeutics' EPS (Basic) stood at -$790.0 in 2021, then surged by 99.96% to -$0.32 in 2022, then soared by 31.25% to -$0.22 in 2023, then soared by 368.18% to $0.59 in 2024, then tumbled by 369.49% to -$1.59 in 2025.
  • The last three reported values for EPS (Basic) were -$1.59 (Q4 2025), -$1.87 (Q3 2025), and -$2.95 (Q2 2025) per Business Quant data.